OncoMatch/Clinical Trials/NCT06007690
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Is NCT06007690 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for choroidal melanoma.
Treatment: Bel-sar · Suprachoroidal Microinjector · Infrared Laser · Sham Infrared Laser · Sham Microinjector — The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Prior therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Retina Consultants of Alabama · Birmingham, Alabama
- UCSD Shiley Eye Institute, Jacobs Retina Center · La Jolla, California
- Doris Stein Eye Research Center · Los Angeles, California
- Stanford University School of Medicine · Palo Alto, California
- Retinal Consultants Medical Group, Inc. · Sacramento, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify